Stifel assumes coverage on Celcuity stock with Buy rating, $30 target

Stifel has initiated coverage on Celcuity (NASDAQ:CELC) with a Buy rating and a $30.00 price target, citing the significant potential of its lead cancer treatment, gedatolisib, to become a standard-of-care in HR+/HER2- metastatic breast cancer, projecting over $2.5 billion in peak sales. Despite reporting a wider-than-expected Q1 2025 loss, Celcuity maintains a strong financial position with $205.7 million in cash and investments, sufficient to fund operations through 2026. The firm highlights gedatolisib's differentiated potency and comprehensive pathway suppression, with the upcoming Q3 2025 topline VIKTORIA-1 data representing a favorable risk/reward opportunity for the stock, currently trading at $13.35.

Analysis

Stifel has initiated coverage on Celcuity (CELC) with a Buy rating and a $30.00 price target, representing substantial upside from its current $13.35 price, driven by the potential of its lead cancer treatment, gedatolisib. The firm projects peak sales exceeding $2.5 billion, viewing the drug as a differentiated asset poised to become a standard-of-care in metastatic breast cancer due to its comprehensive pathway suppression and favorable safety profile. This bullish outlook is counterbalanced by recent financial performance, as Celcuity reported a wider-than-expected Q1 2025 net loss of $37 million ($0.86 per share) due to increased R&D expenses. However, this operational cash burn is mitigated by a strong balance sheet, featuring more cash than debt and a cash position of $205.7 million, which is projected to fund operations through 2026. The primary forward-looking catalyst is the topline data from the VIKTORIA-1 trial, expected in Q3 2025, which Stifel believes presents a favorable risk/reward opportunity that could validate the drug's competitive positioning and significantly impact investor perception.

Key Decisions for Investors

• Investors should view Celcuity as a high-risk, high-reward investment primarily driven by the clinical and commercial potential of its lead asset, gedatolisib, with Stifel's $30 price target highlighting significant potential upside contingent on trial success.
• The pivotal catalyst is the topline VIKTORIA-1 data expected in Q3 2025; a positive outcome could materially de-risk the asset and unlock value, while a failure would severely impair the stock's valuation.
• While the company's cash position of $205.7 million provides a runway through 2026, it is crucial to monitor the cash burn rate, as the wider-than-expected Q1 loss underscores the financial execution risk inherent in pre-revenue biopharmaceutical development.